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Abstract Primary Sjögren’s syndrome (pSS) is a chronic
multisystem autoimmune rheumatic disease characterised by
female predominance. Although the disease is rare in the male
and paediatric populations, it has been suggested that it may
have a different disease phenotype, which has not been inves-
tigated before using a systematic approach. A systematic lit-
erature search of PubMed databases (updated to December
2016) was performed to identify all published data on the
epidemiological, clinical and laboratory manifestations of
pSS in the male and paediatric populations. The literature
search of the male and paediatric pSS studies identified 2025
and 186 citations, respectively, out of which 7 and 5 fulfilled
our inclusion criteria and were analysed further. The range of
age at disease onset was 9.4–10.7 years for children and 39.4–
56.9 years at diagnosis for male patients. We identified a prev-
alence of extra-glandular manifestations between 52.6–92.3%
in the male population and 50.0–84.6% in children, while
abnormal sialometry was only reported in the paediatric pop-
ulation, with a prevalence between 71.4 and 81.8%. There was
a significant variation of positive serological markers, with
anti-Ro antibodies reported between 15.7–75.0% and 36.4–
84.6%, and anti-La antibodies between 5.6–51.7% and 27.3–
65.4%, in the male and paediatric populations, respectively.
The characteristics of pSS in the male and paediatric popula-
tions varied according to different studies. When compared to
data available from pSS adult populations, children diagnosed
with pSS reported less dryness and had a higher prevalence of
parotitis, lymphadenopathy and systemic symptoms and male
patients were younger at the time of diagnosis. This systematic
review contributes to a better understanding of the epidemiol-
ogy of pSS in rare populations. Large longitudinal cohort
studies comparing male with female patients and adult with
paediatric patients are needed.
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Introduction
Primary Sjögren’s syndrome (pSS) is a chronic multisystem
autoimmune rheumatic disease, associated in the majority of
cases with infiltration of exocrine glands, particularly the sali-
vary and lacrimal glands, by lymphocytes and plasma cells,
resulting in xerostomia and xerophthalmia. pSS is a heteroge-
neous disease; clinical manifestations range from localised
glandular disease to complex and even life-threatening systemic
features affecting the neurological, renal, musculoskeletal, der-
matological, haematological, and pulmonary systems. This au-
toimmune rheumatic disease is 9–20 times more common in
females than males according to different studies [1–4], and
although commonest between the ages of 30 and 60, it is also
described in younger and older age groups [5]. There is a sim-
ilar female predominance in the paediatric population
(F:M = 5–7:1) [6, 7]. The prevalence of pSS in the general
population ranged in Greece from 0.09 to 0.23% [4, 8], in
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the UK from 0.14 to 1.60% [9] and in Slovenia was estimated at
0.60% [10].
In 2016, newly updated classification criteria were pub-
lished by the American College of Rheumatology/European
League Against Rheumatism [11, 12]. The proposed classifi-
cation criteria weigh 5 criteria items with a score of either 1 or
3 and a total score of at least 4/9, in the absence of any exclu-
sion criteria, is required for a diagnosis. These weighted
criteria improve on the previous American-European
Consensus Group (AECG) and American College of
Rheumatology (ACR) classification criteria by ensuring that
a positive anti-SSA/Ro or salivary gland biopsy is required for
a diagnosis. Along with other changes, in the absence of anti-
SSA/Ro, anti-SSB/La is no longer considered a criteria item.
Methods
Search strategy
We performed a systematic literature search of PubMed,
covering papers published between January 1984 and
December 2016. In search of the articles on the male
population with Sjögren’s syndrome, we used the fol-
lowing MeSH terms: ‘Sjögren’s syndrome’ and ‘men’
OR ‘male’. To identify relevant publications on the
paediatric population, we used ‘Sjögren’s syndrome’
and ‘child’ OR ‘paediatrics’ as MeSH terms. The auto-
matically selected papers were manually screened by
reading the titles and abstracts. Both searches were lim-
ited to human studies and English language publica-
tions but no limitations were based on the country of
origin or ethnicity of patients. Following the selection
of articles that met the inclusion criteria, their refer-
ences were reviewed for any relevant papers that had
been missed by the PubMed search, and relevant stud-
ies were added to the final analysis.
Study selection
The study selection was carried out independently by
two authors (SV and JGB) based on the inclusion
criteria mentioned above, and subsequently com-
pared—any discrepancies were discussed with the third
author (CC) and a consensus was reached. The general
exclusion criteria applied by authors were the follow-
ing: incorrect patient groups (female cohort, secondary
Sj gren’s syndrome, patients selected based on specific
comorbidities), incorrect study types (case reports, in-
terventional studies, editorials, commentaries, surveys
and questionnaires), studies that analysed therapeutics,
quality of life or cost-benefit analysis and genetic, lab-
oratory or pathology studies. The full texts of the
remaining articles were read and the above criteria were
further applied.
The data from the eligible articles was then extracted and
analysed. The study selection process is detailed in Fig. 1. One
article (retrieved as a reference in another paper) was excluded
from the final analysis, as despite our attempts to contact the
author, the full text could not be retrieved [13].
Data extraction
We extracted data on epidemiological (study type, num-
ber of patients, country of origin, etc.), clinical and
laboratory features and presented it in four tables.
Table 1 details the epidemiological data on both male
and paediatric populations. In Table 2, we included in-
formation related to the clinical features associated with
pSS in both populations. The laboratory data were
organised into two tables (Tables 3 and 4) as the data
set analysed differed between the male and paediatric
population. Any data reported as percentages were con-
verted to actual number of patients to allow us to cal-
culate ranges of data across all the studies analysed.
Assessment of study quality
We used a critical appraisal tool (The Joanna Briggs
Institute Prevalence Critical Appraisal Tool) designed
for use in systematic reviews addressing questions of
prevalence to assess the quality of our studies [14].
The appraisal tool comprises nine assessment questions
related to the quality of studies including the popula-
tion representativeness, recruitment strategy, sample
size, description of study subjects, use of objective,
standard criteria for subject classification, quality of
outcome measurements, appropriate statistical analysis,
identification of confounding factors and identification
of subpopulations, where appropriate. These criteria
were assessed as present, absent, unclear or not appli-
cable, as per the methodological guidance published for
this critical appraisal tool [15]. The assessment was
completed by all three authors independently and a
consensus was reached for every study. Because of
the low prevalence of pSS in the paediatric and male
populations, the majority of the studies evaluated co-
horts from secondary and tertiary centres and used var-
ious classification criteria (justified by the lack of clas-
sification criteria in the paediatric population, and var-
ious revisions of classification criteria for adult pSS
over time). In addition, the measurement of different
clinical manifestations was not standardised and it re-
lied on medical records and expert opinion. The data
analysis did not have significant coverage of the iden-
tified sample as, in the majority of studies, the
Clin Rheumatol
paediatric cases were not compared with adult patients,
and the male case was pre-selected and compared to
consecutive female case series from a different cohort.
A compromise was made by the authors to include papers
which used different classification criteria for pSS because of
the small number of studies available in the male and
paediatric populations. Consequently, and in addition to the
lack of fulfilment of the majority of the nine questions includ-
ed in the appraisal checklist and because of the high study
heterogeneity, we could not calculate reliable pooled preva-
lence rates for different disease manifestations and perform a
meta-analysis.
Records idenﬁed through
database searching
(n = 2024)
Idenﬁcaon Addional records idenﬁed
through other sources
(n = 1)
Records screened
(n = 2025)
Records excluded applying
exclusion criteria
(n = 1992)
Full-text arcles assessed
for eligibility
(n = 33)
Studies included in
systemac review
(n = 7)
Records aer duplicates removed
(n = 2025)
Full-text arcles excluded, with
reasons (n = 25):
Incorrect study type (case
report, case series, chart
review study) (n=12)
Incorrect paent group
(female populaon, secondary
Sjögren’s, speciﬁc subset
populaons) (n=13)
Full-text not available (n=1)
Duplicates removed
(n=0)
Included
Eligibility
Screening
Idenﬁcaon Addional records idenﬁed
through other sources
(n = 5)
Records idenﬁed through
database searching
(n = 181)
Total records idenﬁed
(n = 186)
Full-text arcles excluded, with
reasons (n = 30):
Incorrect study type (case report,
case series, chart review study)
(n=21)
Incorrect paent group (adult
populaon, secondary Sjögren’s,
speciﬁc subset populaons) (n=8)
Low number of paents) (n=1)
Full-text not available (n=5)
Eligibility
Included Studies included in
qualitave synthesis
(n = 5)
Full-text arcles assessed
for eligibility
(n = 36)
Duplicates removed
(n = 0)
Records excluded based on reading
the tles and abstracts and applying a
general exclusion criteria
(n = 150)
Records screened
(n = 186)
Screening
a
b
Fig. 1 a Flowchart of study
selection for papers referring to
the pSS male population. b
Flowchart of study selection for
papers referring to pSS paediatric
populations
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Results
Demographics/epidemiological
After assessment of study quality, we included data from
seven studies on the male population [16–22] and five on
the paediatric population [22–26]; this data is presented in
Table 1. The total adult male cohort included in our sys-
tematic review consisted of 210 patients (range 12–60
patients/per study). The paediatric cohort consisted of
132 patients (range 11–42 patients/per study). All of the
male papers included comparisons with female patient
population, while in the paediatric studies, only one study
compared children with adult pSS population [23]. Three
studies reported on patients from the American population,
eight were European and one was Japanese. The criteria for
patient inclusion varied. In the male studies, four papers
used the European Community Study Group (ECSG) clas-
sification [27], two papers used the 2002 AECG [28] and
one paper used its own personal criteria (Table 1). One
paediatric study used the ECSG criteria, one used the
European League Against Rheumatism (EULAR) criteria
[29] and the other three studies used different personal
criteria. The mean age of the patients was available for all
studies. However, three different data sets were described:
age at onset, age at presentation and age at diagnosis. Four
out of the five paediatric papers included in our final anal-
ysis quoted age at onset (range 9.5–10.7 years). Across the
cohort of paediatric patients, where reported, the
female:male ratio was 8:1.
Clinical features
The data regarding clinical features are presented in Table 2.
Glandular features
Data about the prevalence of parotitis were available in 10 out
of 12 studies. A total of 35 adult male and 76 paediatric pa-
tients presented with parotitis as a manifestation of pSS (range
15.8–35.7% and 35.7–76.9%, respectively). All studies re-
ported on dryness, although this was classified as ‘any sicca’
symptoms in some studies and as ‘dry eyes’ and ‘dry mouth’
in others. In the four male studies that reported sicca symp-
toms, these were present in 75.0–100% of patients. In the four
paediatric studies reporting dryness, the subjective sicca
symptoms were present in 23.1– 80.8% of patients.
Extra-glandular features
The presence of any extra-glandular features was described in
four papers reporting on the male population and in two of the
paediatric papers. A proportion of 52.6–92.3% of male
patients and 50.0–84.6% of paediatric patients had these man-
ifestations. Joint involvement was the most commonly
ascertained data set (all studies, apart from Stiller et al. 2000
( [25]) reported on it). Joint involvement, defined as arthritis or
arthralgia, was reported in 8.3– 77.8% of male patients and
10.0–57.7% of paediatric patients. Only two papers reported
separately on arthritis and arthralgia in male population with
pSS, arthralgia being found in 18/28 and 5/6 of patients with
joint involvement, respectively [16, 17]. Raynaud’s, pulmo-
nary and neurological involvement were reported in both the
male (8.3–28.6%, 0.0–19.8% and 10.5–38.9%, respectively)
and paediatric populations (0.0–30.8%, 2.4% and 5.0–23.1%,
respectively). Renal involvement and lymphadenopathy were
found in children in the following proportions in different
studies: 7.1–19.2% and 7.5–46.2%, respectively, while the
frequency of these symptoms was lower in the male popula-
tion (2.8–7.7% and 4.8–33.3%, respectively). Many other
extra-glandular features were occasionally reported; of note,
there was a high prevalence of fever (52.4%) and dental caries
(57.7%) reported by two paediatric studies [23, 26].
Laboratory features
Due to variation of the laboratory features reported between
the male and paediatric studies, the data has been presented
separately (in Tables 3 and 4). With the exception of one
paper, which reported on the presence of anti-extractable nu-
clear antigen (ENA) antibodies [24], all papers were reported
on the core serology—the presence of anti-SSA (Ro), anti-
SSB (La), anti-nuclear antibodies (ANA) and rheumatoid fac-
tor (RF). Anti-SSA, anti-SSB, ANA and RF were positive in
15.7–75.0%, 5.6–51.7%, 33.3–84.6%, 22.2–72.7%, respec-
tively, in the male population, and 36.4–84.6%, 27.3–65.4%,
63.6–96.2%, 27.3–75.0%, respectively, in the paediatric pop-
ulation, suggesting a high variability between different stud-
ies. Cryoglobulinaemia was only reported in the male popu-
lation (in four out of seven studies) with a prevalence of 6.7–
19.0%. A number of other serological markers were occasion-
ally reported (Tables 3 and 4).
Data on non-serological investigations were available for
the paediatric population and included pathological biopsy,
sialometry, scintigraphy, ocular stains and sialography. In the
male population, only salivary gland biopsy data were retriev-
able from the papers included in our analysis, with a propor-
tion of 93.5–100% patients having a positive biopsy. In the
paediatric population, a pathological biopsy ranged from 66.7
to 100%; two out of the four studies described no criteria for
defining the histological criteria used for pSS classification.
In Table 5 (supplementary information), we summarised
the main differences between male and female populations,
and paediatric and adult populations as reported by the studies
included in our analysis; however, comparisons between this
systematic review and data available from other systematic
Clin Rheumatol
reviews in adult pSS populations were beyond the purpose of
this paper.
Discussion
Although pSS is an autoimmune disease with well-
recognised female predomination, a proportion of up
to 10% of adult patients diagnosed with this condition
are male. In the paediatric population, the female to
male ratio is 6–7:1 [24, 30]. The diagnosis of pSS in
children is delayed, in many cases, because children
less frequently report dryness due to their good saliva
and tear reserve and frequently present with extra-
glandular clinical features suggestive of other autoim-
mune diseases [31]. Although the disease burden is
significant in both male and paediatric populations,
good quality studies are lacking. To our knowledge,
this is the first attempt to review systematically the
literature on male and paediatric populations with pSS.
Many of the studies we selected based on our inclusion
criteria involved the selection of relevant paediatric or male
cases from large cohorts.
The classification criteria for pSS were revised several
times in the last few years and again very recently [11, 12];
therefore, different inclusion criteria were used in different
studies. The main difference between the ECSG [29] and
AECG [28] classification criteria is that the AECG criteria
require the presence of positive biopsy or serology tests to
classify patients as having pSS. In addition, the AECG criteria
also mention the need to exclude mimicking pathology, such
as head and neck radiation treatment, hepatitis C and use of
anticholinergic drugs.
We have taken into consideration that a comparison
between studies including patients classified in different
ways might lead to erroneous conclusions; therefore, we
presented the results as intervals of proportions of pa-
tients reported as having different disease manifesta-
tions. A pooled prevalence meta-analysis could not be
performed because of the high heterogeneity of the pa-
tient population, which would have led to unreliable
conclusions.
A significant proportion of studies (5/12) included a low
number of patients (less than 20). Although all the male stud-
ies also evaluated a certain number of female patients, the
male cases were pre-selected (because of their rarity) and com-
pared to a variable number of consecutive female cases (there-
fore, all the studies were affected by patient selection bias).
One of the other limitations of this systematic analysis was
the selection of paediatric studies which relied on expert opin-
ion for diagnosis, which is the consequence of lack of specific
classification criteria for paediatric pSS. It is recognised that
the available classification criteria designed for adult pSS
population have significant limitations when used in children
[32].
One of the main conclusions of this systematic analysis
was that parotid gland involvement was common in children
with pSS despite being recognised that, with the exception of
mumps parotitis, all other causes of parotitis in children are
rare [33]. Parotitis is therefore recognised as a characteristic
disease feature in paediatric pSS [31]. Sicca symptoms were
less common in children for the reasons discussed above.
Symptoms of dryness are recognised to be more common in
the adult population affected by pSS because of the correlation
between the destruction of the acinar cells and age [34, 35].
Despite this, the symptoms of eye dryness were reported with
a high variability in the male studies, with a prevalence range
of 38.9–94.7%.
We also found that in the paediatric population, constitu-
tional symptoms and lymphadenopathy were prevalent, which
can be explained by a particular disease phenotype in children
or other confounders (frequent associated viral infection dur-
ing childhood, parental vigilance in detecting high tempera-
ture, etc.). However, lymphadenopathy despite being general-
ly less commonly reported in the adult population, it was
found as more common in male than female patients in only
one study [18]. The joint involvement in adult pSS, partly
explained by the disease phenotype and partly by the age-
related associated joint pathology, showed no specific trend
in the male versus female population, as the studies included
in our analysis reported inconsistent data ( [18], [20], [22]).
There was a significant variation of positive serological
markers in both the male and paediatric populations. As the
quality of studies and patient classification criteria used were
very heterogeneous, we cannot infer any reliable comparison
with the reported positive serology prevalence from pSS adult
studies [36]. The trend towards a higher positive serology
prevalence in children can be explained again by the difficulty
to diagnose pSS in children with reasonably well-preserved
exocrine gland secretion without specific serology, and could
explain the need for additional investigations to facilitate the
diagnosis (we found that invasive investigations, such as scin-
tigraphy, sialometry and biopsy were more frequently per-
formed in paediatric studies). It was previously identified that
the presence of antibodies directed against the Ro/La ribonu-
cleoprotein complexes have been correlatedwith younger age,
more severe dysfunction of the exocrine glands and a higher
prevalence of extra-glandular manifestations in the adult pop-
ulation [36]. Our systematic analysis identified a prevalence of
extra-glandular manifestations between 52.6–92.3% in the
male population and 50.0–84.6% in children, while abnormal
sialometry was reported only in the paediatric population,
with a prevalence between 71.4 and 81.8%.
A case series of children with pSS reported that although
the serological markers were not relevant for diagnosis, all
patients had specific lymphocytic infiltration of labial salivary
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glands and sialectasis [37]; subsequently, the authors conclud-
ed that salivary and lachrymal gland histopathology in this age
group is highly recommended for accurate diagnosis.
Previous research comparing pSS patients with early and
late disease onset found no significant differences between
their clinical presentation and incidence of diagnostic test pos-
itivity; however, the early onset of pSS was defined as diag-
nosis before the age of 40 and the study did not include chil-
dren [5]. A recent systematic review and meta-analysis of pSS
epidemiology reported a female/male ratio in prevalence rate
for pSS of 10.72:1, without providing details about the differ-
ences in clinical presentation or laboratory features of pSS in
female compared to male patients [38].
In summary, this systematic review found that children
diagnosed with pSS reported less frequently symptoms of
dryness, and had a higher prevalence of systemic symptoms,
including fever and lymphadenopathy, as well as parotitis, in
comparison to adult populations [39, 40].
Male patients with pSS were younger at the time of diag-
nosis than the pooled aged at diagnosis in the general pSS
adult population, as estimated by a recent systematic review
and meta-analysis [38]; however, male patients did not have
any consistently different clinical or serological features when
compared to female pSS patients in different studies, which
can be explained by different pSS classification criteria used,
patient selection bias or true heterogeneity of the male pSS
population.
Our systematic review highlighted the difficulties related to
data collection in rare populations. In addition, the different
clinical presentation and absence of validated classification
criteria for the paediatric population with pSS in comparison
to the adult population makes reliable diagnosis very difficult
and highly dependent on expert opinion.
We also found that despite the increased clinician interest in
defining different disease phenotypes, such as male and pae-
diatric pSS, all the studies available came from developed
countries and their conclusions are difficult to extrapolate.
In conclusion, our systematic review highlighted the most
commonly reported clinical manifestations and serological
markers of pSS in male and children population, raising clini-
cians’ awareness about particular disease features in popula-
tions rarely affected by pSS. This could have significant im-
plications in facilitating the diagnosis of pSS in male and
children. Future work, including large longitudinal cohort
studies comparing male versus female patients, and adult ver-
sus paediatric patients, will enable us to differentiate reliably
the disease presentation and evolution in these selected cate-
gories of patients.
Significance and innovation
– This is the first systematic review of pSS in rare
populations
– Large, multicentre, good-quality studies of pSS in rare
populations and classification criteria for pSS in paediat-
ric population are lacking
– Children with pSS have less dryness, and more frequently
experienced systemic symptoms and parotid enlargement
– There were no consistent differential features of male pSS
patients when compared to adult female patient
population
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